GRFS – Grifols, S.A.
GRFS — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
1.34
Margin Of Safety %
34
Put/Call OI Ratio
0.73
EPS Next Q Diff
EPS Last/This Y
0.5
EPS This/Next Y
0.28
Price
7.54
Target Price
12.93
Analyst Recom
2.25
Performance Q
Upside
N/A
Beta
0.67
Ticker: GRFS
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-09-28 | GRFS | 7.41 | 0.84 | 4.00 | 5885 |
| 2026-09-29 | GRFS | 7.3 | 0.84 | 4.00 | 5885 |
| 2026-09-30 | GRFS | 7.31 | 0.84 | 4.00 | 5892 |
| 2026-10-01 | GRFS | 7.3 | 0.84 | 0.20 | 5892 |
| 2026-10-02 | GRFS | 7.3 | 0.85 | 999.99 | 5900 |
| 2026-10-05 | GRFS | 7.41 | 0.85 | 0.00 | 5900 |
| 2026-10-06 | GRFS | 7.53 | 0.85 | 1.14 | 5893 |
| 2026-10-07 | GRFS | 7.49 | 0.87 | 0.00 | 5898 |
| 2026-10-08 | GRFS | 7.4 | 0.87 | 0.00 | 5899 |
| 2026-10-09 | GRFS | 7.45 | 0.87 | 0.00 | 5899 |
| 2026-10-12 | GRFS | 7.36 | 0.81 | 3.60 | 6158 |
| 2026-10-13 | GRFS | 7.19 | 0.81 | 0.04 | 6170 |
| 2026-10-14 | GRFS | 7.24 | 0.81 | 0.04 | 6157 |
| 2026-10-15 | GRFS | 7.54 | 0.80 | 0.00 | 6215 |
| 2026-10-16 | GRFS | 7.65 | 0.80 | 0.13 | 6215 |
| 2026-10-19 | GRFS | 7.62 | 0.79 | 0.00 | 6259 |
| 2026-10-20 | GRFS | 7.53 | 0.77 | 0.00 | 6311 |
| 2026-10-21 | GRFS | 7.51 | 0.77 | 0.00 | 6312 |
| 2026-10-22 | GRFS | 7.45 | 0.77 | 0.00 | 6312 |
| 2026-10-23 | GRFS | 7.55 | 0.73 | 0.00 | 6540 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-09-28 | GRFS | 7.41 | - | - | 1.16 |
| 2026-09-29 | GRFS | 7.30 | - | - | 1.16 |
| 2026-09-30 | GRFS | 7.30 | - | - | 1.16 |
| 2026-10-01 | GRFS | 7.30 | - | - | 1.16 |
| 2026-10-02 | GRFS | 7.31 | - | - | 1.16 |
| 2026-10-05 | GRFS | 7.42 | - | - | 1.16 |
| 2026-10-06 | GRFS | 7.54 | - | - | 1.16 |
| 2026-10-07 | GRFS | 7.50 | - | - | 1.16 |
| 2026-10-08 | GRFS | 7.39 | - | - | 1.16 |
| 2026-10-09 | GRFS | 7.45 | - | - | 1.16 |
| 2026-10-12 | GRFS | 7.36 | - | - | 1.16 |
| 2026-10-13 | GRFS | 7.20 | - | - | 1.16 |
| 2026-10-14 | GRFS | 7.24 | - | - | 1.16 |
| 2026-10-15 | GRFS | 7.54 | - | - | 1.16 |
| 2026-10-16 | GRFS | 7.63 | - | - | 1.16 |
| 2026-10-19 | GRFS | 7.63 | - | - | 1.16 |
| 2026-10-20 | GRFS | 7.63 | - | - | 1.16 |
| 2026-10-21 | GRFS | 7.54 | - | - | 1.16 |
| 2026-10-22 | GRFS | 7.45 | - | - | 1.16 |
| 2026-10-23 | GRFS | 7.54 | - | - | 1.16 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
No data found
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
0.3
Avg. EPS Est. Next Quarter
0.39
Insider Transactions
Institutional Transactions
-2.53
Beta
0.67
Average Sales Estimate Current Quarter
1969
Average Sales Estimate Next Quarter
2170
Fair Value
10.13
Quality Score
59
Growth Score
72
Sentiment Score
72
Actual DrawDown %
46
Max Drawdown 5-Year %
-60.6
Target Price
12.93
P/E
10.23
Forward P/E
6.49
PEG
0.28
P/S
0.24
P/B
0.85
P/Free Cash Flow
2.17
EPS
0.77
Average EPS Est. Cur. Y
1.16
EPS Next Y. (Est.)
1.44
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
6.09
Relative Volume
0.35
Return on Equity vs Sector %
-17.5
Return on Equity vs Industry %
-27
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
No data found for GRFS
GRFS — P/E HistoricalDrug Manufacturers - General
Grifols, S.A.Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 25258
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.
GRFS
Latest News
—
Caricamento notizie per GRFS…
stock quote shares GRFS – Grifols, S.A. Stock Price stock today
news today GRFS – Grifols, S.A. stock forecast ,stock prediction 2023 2024 2025
marketwatch GRFS – Grifols, S.A. yahoo finance google finance
stock history GRFS – Grifols, S.A. invest stock market
stock prices GRFS premarket after hours
ticker GRFS fair value insiders trading